Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of NuGenerex.

    Client Virtual Booth

    NUGENEREX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    NuGenerex
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Miramar, Florida 33025
    Telephone
    Telephone
    +1-954- 919-5123
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nugenerexdiagnostics.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    NuGenerex Closes Licensing & Distribution Agreement with Bintai Kinden to Advance Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets

    Details:

    Bintai obtains the exclusive license to distribute the Ii-Key-SARS-CoV-2 vaccine in Southeast Asia, including Malaysia, Vietnam, Indonesia, and the Philippines.


    Lead Product(s): Ii-Key-SARS-CoV-2 vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: N/AProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Bintai Kinden

    Deal Size: Undisclosed Upfront Cash: $3.0 million

    Deal Type: Licensing Agreement October 07, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    NuGenerex Immuno-Oncology Closes $50 Million Financing Facility

    Details:

    NuGenerex Immuno-Oncology is developing immunotherapeutic Ii-Key peptide vaccines for cancer and infectious diseases.


    Lead Product(s): AE37 Peptide,Pembrolizumab

    Therapeutic Area: Oncology Product Name: AE37

    Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: $50.0 million Upfront Cash: Undisclosed

    Deal Type: Financing July 15, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search